Alpha-1 antitrypsin deficiency is a genetic condition that requires lifelong management to protect the lungs and liver from progressive damage. Treatment strategies combine lifestyle changes, symptom management, and specialized therapies designed to slow disease progression and maintain quality of life. While there is no cure, early diagnosis and appropriate intervention can make a significant difference in outcomes.

How Treatment Helps People with Alpha-1 Antitrypsin Deficiency

The main goal of treating Alpha-1 antitrypsin deficiency is to protect your lungs from further damage and manage symptoms that affect your daily life. Because this condition causes low levels of a protective protein called alpha-1 antitrypsin (AAT), your lungs become vulnerable to harm from inflammation and environmental irritants. Treatment focuses on raising AAT levels in your lungs, reducing inflammation, and preventing complications like emphysema, which is a form of chronic obstructive pulmonary disease (COPD) where the air sacs in your lungs lose their shape and make breathing difficult.^[1]

Treatment plans vary depending on which organs are affected, how severe your symptoms are, and whether you smoke or have other risk factors. Some people with Alpha-1 may not develop symptoms at all, while others may experience progressive lung disease between ages 20 and 50.^[6] The condition can also affect the liver, particularly in children, though this is less common in adults. Because Alpha-1 is inherited and affects people differently, doctors tailor treatment to each person’s specific situation.

There are established treatments recommended by medical societies based on decades of clinical experience. These include medications to help you breathe more easily, prevent infections, and in some cases, replace the missing AAT protein. Beyond these standard approaches, researchers are exploring new therapies in clinical trials, testing innovative ways to address the root causes of the disease and improve long-term outcomes.^[14]

Standard Treatment Approaches

Medications to Manage Breathing and Lung Symptoms

The initial treatment for lung problems caused by Alpha-1 deficiency is similar to treatment for emphysema and COPD. These medications don’t cure the condition, but they help reduce symptoms and improve your ability to breathe comfortably. Bronchodilators are often the first medicines prescribed. These work by relaxing the muscles around your airways, making it easier for air to move in and out of your lungs. Bronchodilators come in two types: short-acting ones that last about four to six hours and are used when you feel breathless, and long-acting versions that last 12 hours or more and are taken daily to maintain steady breathing function.^[13]

Inhaled corticosteroid medications may also be prescribed to reduce inflammation in your airways. These are different from bronchodilators because they address the swelling and irritation that narrow your breathing passages. While they can be very helpful, they may cause side effects such as bruising, hoarseness, or oral infections, so your doctor will monitor you for these problems.^[13]

When you develop a respiratory infection, such as bronchitis or a flare-up of your lung symptoms, antibiotics are important. Because people with Alpha-1 are more vulnerable to lung infections, which can cause further damage, your doctor may recommend starting antibiotics early during any bout of illness. Frequent chest infections are common in people with this condition, so prompt treatment helps prevent complications.^[1]

Augmentation Therapy: Replacing the Missing Protein

The only treatment specifically designed for Alpha-1 antitrypsin deficiency is called augmentation therapy, also known as replacement therapy. This treatment is approved for adults who have emphysema and severely low levels of AAT protein. It works by giving you AAT protein that has been collected from the blood plasma of healthy donors. Through a process of careful screening and purification, this protein is prepared as an intravenous medicine.^[9]

Five augmentation therapies have been approved by the U.S. Food and Drug Administration: Prolastin-C, Prolastin-C Liquid, Aralast NP, Zemaira, and Glassia. All work in the same basic way. You receive a weekly infusion of AAT directly into your bloodstream through an IV catheter inserted into a vein in your arm, or through a small device called a port that is surgically placed under the skin of your chest. The infusion raises AAT levels in your blood and lungs to a range that can protect your lung tissue from being broken down by enzymes released during inflammation.^[9]

Augmentation therapy cannot reverse lung damage that has already occurred or restore lung function that has been lost. However, well-designed studies have shown that this treatment helps preserve lung function over time and decreases the number and severity of lung infections. It works by slowing the loss of lung tissue density, which means the disease progresses more slowly. This can help you maintain your quality of life and ability to perform daily activities for longer.^[14]

Most people tolerate augmentation therapy well, with only mild side effects. Some individuals may experience headaches, dizziness, or fatigue after infusions. More rarely, people might have allergic reactions. Because the treatment is ongoing—given every week for the rest of your life—many patients receive their infusions at home with the help of a family member or a nurse. This allows for more flexibility and comfort compared to going to a clinic each week.^[9]

It’s important to know that augmentation therapy is not appropriate for everyone with Alpha-1. It is specifically recommended for people who have emphysema and documented deficiency of the AAT protein. It is not used to prevent lung disease in people who have the genetic deficiency but no symptoms, and it is not typically used for liver disease.^[9]

Vaccinations and Infection Prevention

Because your lungs are more vulnerable to infection when you have Alpha-1 deficiency, preventing infections is a key part of treatment. Doctors strongly recommend that you get a flu vaccine every year, as influenza can lead to serious complications in people with weakened lungs. You should also receive the pneumococcal vaccine, which protects against bacteria that cause pneumonia and other infections. Depending on the type of pneumococcal vaccine, you may need this every three to five years.^[8]

Vaccines for hepatitis are also recommended because the virus can cause additional liver damage in people who already have Alpha-1-related liver problems. Your doctor may suggest other vaccines based on your specific health situation and risk factors.^[8]

Oxygen Therapy and Pulmonary Rehabilitation

As lung disease progresses, some people with Alpha-1 may need supplemental oxygen to maintain healthy oxygen levels in their blood. Oxygen therapy involves using a portable oxygen tank or concentrator to breathe in extra oxygen through a tube placed in your nose. This helps reduce shortness of breath and allows you to stay more active. Your doctor will perform tests to measure your oxygen levels and determine if you need this treatment.^[10]

Pulmonary rehabilitation is a comprehensive program that combines exercise training, education about managing your condition, nutritional counseling, and psychological support. It’s designed to improve your physical stamina, teach you breathing techniques, and help you cope with the emotional challenges of living with a chronic lung disease. Studies show that pulmonary rehabilitation can significantly improve quality of life, reduce breathlessness, and increase your ability to perform everyday tasks.^[13]

Surgical Options for Advanced Disease

In severe cases where lung damage is extensive and other treatments are not sufficient, surgery may be considered. Lung transplantation involves removing one or both damaged lungs and replacing them with healthy lungs from a deceased donor. While a transplant can dramatically improve lung function and quality of life, it carries significant risks, including infection, rejection of the new organ, and the need for lifelong immunosuppressive medications to prevent rejection. Not everyone is a candidate for transplant, and the decision involves careful evaluation by a specialized medical team.^[8]

Other surgical procedures include lung volume reduction surgery, where doctors remove the most damaged parts of the lung to allow the healthier sections to work better, and bullectomy, which removes large air-filled spaces (called bullae) that form in damaged lungs. These procedures are less common and are considered experimental in some cases. There are also newer techniques being studied, such as placing valves or coils into airways to shrink emphysematous areas and improve breathing.^[13]

For people with severe liver disease from Alpha-1, liver transplantation may be necessary. This is more common in children who develop liver cirrhosis, but some adults may also need it. Like lung transplant, liver transplant is a major surgery with serious risks and requires lifelong follow-up care.^[2]

Duration and Monitoring of Treatment

Treatment for Alpha-1 antitrypsin deficiency is lifelong. Augmentation therapy continues indefinitely as long as it remains beneficial. Other medications, such as bronchodilators and inhaled steroids, are adjusted based on your symptoms and lung function tests. Your doctor will monitor you regularly with spirometry, a breathing test that measures how much air you can move in and out of your lungs, and other lung function tests to track disease progression and treatment effectiveness.^[12]

Imaging tests such as CT scans of the chest may be done periodically to assess lung damage. Blood tests check AAT levels and liver function. These monitoring tools help your healthcare team make informed decisions about adjusting your treatment plan as your condition changes over time.^[12]

Innovative Therapies Being Tested in Clinical Trials

While standard treatments focus on managing symptoms and slowing disease progression, researchers are actively working on new approaches that could change how Alpha-1 deficiency is treated in the future. Clinical trials are testing several promising therapies that target different aspects of the disease.^[14]

Understanding Clinical Trial Phases

Before we discuss specific treatments, it helps to understand how clinical trials work. New therapies progress through three main phases. Phase I trials test a new drug or treatment in a small group of people to evaluate its safety, determine safe dosage ranges, and identify side effects. Phase II trials involve more participants and focus on whether the treatment actually works—does it improve symptoms, slow disease progression, or achieve other therapeutic goals? Phase III trials compare the new treatment to current standard treatments in large groups of people to confirm effectiveness, monitor side effects, and collect information that will help doctors use the treatment safely.^[14]

Gene Therapy Approaches

Because Alpha-1 deficiency is caused by mutations in the SERPINA1 gene, scientists are exploring gene therapy as a potential cure. This approach would involve delivering a correct copy of the gene into the liver cells, allowing them to produce normal AAT protein. Several research groups are working on different methods to accomplish this, including using modified viruses as delivery vehicles to carry the healthy gene into cells. While gene therapy is still in early research stages for Alpha-1, it represents an exciting possibility for addressing the root cause of the disease rather than just managing symptoms.^[6]

New Forms of Augmentation Therapy

Researchers are developing alternative ways to deliver augmentation therapy that could be more convenient than weekly infusions. Some studies are testing inhaled forms of AAT protein that would go directly into the lungs, potentially requiring less frequent dosing and avoiding the need for intravenous access. Other approaches include longer-acting formulations of AAT that might be given every two weeks or monthly instead of weekly. These developments could significantly improve quality of life for people receiving augmentation therapy by reducing the treatment burden.^[14]

Small Molecule Drugs That Enhance Protein Function

Some clinical trials are testing small molecule drugs that work by helping the abnormal AAT protein fold correctly and leave the liver, or by enhancing the activity of whatever AAT protein is present. These drugs, which are taken as pills rather than infusions, could potentially increase AAT levels through a completely different mechanism than replacement therapy. While specific drug names and trial results are still emerging, this approach represents a new direction in treating the underlying deficiency.^[14]

Anti-Inflammatory and Immunomodulatory Therapies

Because lung damage in Alpha-1 involves excessive inflammation and the activity of enzymes that break down lung tissue, some researchers are testing therapies that specifically target these inflammatory pathways. This might include drugs that block neutrophil elastase (the enzyme that destroys lung tissue when AAT is deficient) or medications that reduce overall lung inflammation through different mechanisms than standard inhaled steroids. The goal is to protect the lungs from damage even when AAT levels remain low.^[14]

Preliminary Results and Patient Eligibility

Some clinical trials of augmentation therapy have shown promising preliminary results. Studies using computed tomography scans to measure lung density have found that augmentation therapy reduces the loss of lung tissue over time compared to no treatment. Patients receiving augmentation therapy also tend to experience fewer and less severe episodes of lung infection and respiratory symptoms. However, researchers continue to work on proving that these benefits translate into longer life and better quality of life over decades of treatment.^[14]

Clinical trials for Alpha-1 are conducted at medical centers in multiple countries, including the United States, Europe, and other regions. To participate, patients typically need to have confirmed Alpha-1 deficiency with specific genetic mutations, meet certain criteria regarding lung function and symptoms, and not have other serious health conditions that would interfere with the study. If you’re interested in participating in a clinical trial, your doctor can help you find appropriate studies and determine if you’re eligible.^[14]

Most common treatment methods

• Bronchodilators
  • Short-acting bronchodilators that last 4 to 6 hours and are used when needed for breathlessness
  • Long-acting bronchodilators that last 12 hours or more and are taken daily to maintain breathing function
  • Work by relaxing the muscles around airways to make breathing easier
• Inhaled Corticosteroids
  • Reduce inflammation in the airways to improve breathing
  • May cause side effects including bruising, hoarseness, and oral infections
  • Used regularly to control chronic inflammation
• Augmentation Therapy
  • Five FDA-approved products: Prolastin-C, Prolastin-C Liquid, Aralast NP, Zemaira, and Glassia
  • Weekly intravenous infusions of alpha-1 antitrypsin protein collected from healthy donors
  • Raises AAT levels in lungs and blood to protective levels
  • Slows loss of lung density and reduces lung infections
  • Cannot reverse existing lung damage but slows disease progression
  • Only for patients with emphysema and documented AAT deficiency
• Antibiotics
  • Given early during respiratory infections to prevent complications
  • Important because people with Alpha-1 are more vulnerable to lung infections
• Vaccinations
  • Annual flu vaccine to prevent influenza complications
  • Pneumococcal vaccine every 3 to 5 years to prevent pneumonia
  • Hepatitis vaccines to protect liver function
• Oxygen Therapy
  • Supplemental oxygen through portable tanks or concentrators
  • Used when blood oxygen levels are low
  • Reduces shortness of breath and improves activity tolerance
• Pulmonary Rehabilitation
  • Exercise training to improve physical stamina
  • Education about managing the condition
  • Nutritional counseling for optimal health
  • Psychological support for coping with chronic disease
  • Breathing technique instruction
• Surgical Treatments
  • Lung transplantation for severe lung damage with replacement from deceased donor
  • Lung volume reduction surgery to remove most damaged lung sections
  • Bullectomy to remove large air-filled spaces in damaged lungs
  • Liver transplantation for severe liver disease, more common in children
• Lifestyle Modifications
  • Complete smoking cessation, which is essential to prevent rapid lung damage
  • Avoiding secondhand smoke and environmental pollutants
  • Regular exercise tailored to lung capacity
  • Healthy diet with adequate protein, phosphorus, and vitamin D
  • Avoiding alcohol to protect liver function